Citadel Advisors’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-11,600
| Closed | -$81K | – | 15092 |
|
|
2021
Q4 | $81K | Sell |
11,600
-50,100
| -81% | -$524K | ﹤0.01% | 12937 |
|
|
2021
Q3 | $703K | Buy |
61,700
+42,700
| +225% | +$624K | ﹤0.01% | 9058 |
|
|
2021
Q2 | $304K | Buy |
+19,000
| New | +$326K | ﹤0.01% | 11236 |
|
|
2021
Q1 | – | Sell |
-10,600
| Closed | -$143K | – | 13917 |
|
|
2020
Q4 | $143K | Sell |
10,600
-8,100
| -43% | -$97.9K | ﹤0.01% | 9981 |
|
|
2020
Q3 | $220K | Sell |
18,700
-900
| -5% | -$11K | ﹤0.01% | 8657 |
|
|
2020
Q2 | $289K | Sell |
19,600
-5,300
| -21% | -$78.4K | ﹤0.01% | 7975 |
|
|
2020
Q1 | $336K | Buy |
24,900
+8,900
| +56% | +$169K | ﹤0.01% | 7133 |
|
|
2019
Q4 | $387K | Sell |
16,000
-6,800
| -30% | -$141K | ﹤0.01% | 7207 |
|
|
2019
Q3 | $438K | Sell |
22,800
-7,300
| -24% | -$167K | ﹤0.01% | 6966 |
|
|
2019
Q2 | $889K | Buy |
30,100
+3,900
| +15% | +$150K | ﹤0.01% | 5881 |
|
|
2019
Q1 | $1.25M | Buy |
26,200
+6,900
| +36% | +$304K | ﹤0.01% | 5213 |
|
|
2018
Q4 | $697K | Sell |
19,300
-3,800
| -16% | -$178K | ﹤0.01% | 5885 |
|
|
2018
Q3 | $1.42M | Buy |
23,100
+2,800
| +14% | +$180K | ﹤0.01% | 4949 |
|
|
2018
Q2 | $1.37M | Buy |
20,300
+9,200
| +83% | +$515K | ﹤0.01% | 4690 |
|
|
2018
Q1 | $602K | Sell |
11,100
-7,100
| -39% | -$397K | ﹤0.01% | 5585 |
|
|
2017
Q4 | $1.09M | Sell |
18,200
-35,000
| -66% | -$2.12M | ﹤0.01% | 4543 |
|
|
2017
Q3 | $2.59M | Buy |
53,200
+3,400
| +7% | +$186K | ﹤0.01% | 3099 |
|
|
2017
Q2 | $2.62M | Buy |
49,800
+45,200
| +983% | +$2.1M | ﹤0.01% | 2820 |
|
|
2017
Q1 | $209K | Sell |
4,600
-5,300
| -54% | -$236K | ﹤0.01% | 6443 |
|
|
2016
Q4 | $375K | Sell |
9,900
-21,600
| -69% | -$817K | ﹤0.01% | 5347 |
|
|
2016
Q3 | $1.19M | Buy |
+31,500
| New | +$695K | ﹤0.01% | 3605 |
|
|
2016
Q1 | – | Sell |
-3,700
| Closed | -$90K | – | 8320 |
|
|
2015
Q4 | $90K | Sell |
3,700
-17,500
| -83% | -$408K | ﹤0.01% | 6811 |
|
|
2015
Q3 | $376K | Buy |
21,200
+11,600
| +121% | +$210K | ﹤0.01% | 5225 |
|
|
2015
Q2 | $169K | Buy |
+9,600
| New | +$176K | ﹤0.01% | 6524 |
|
Citadel Advisors's AERI Position: Q4 2022 in Review
Citadel Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 228,542 shares — an estimated $3.46M sold.
Citadel Advisors first reported a position in AERI in Q2 2015 and held it in 28 quarters. The position peaked at $85.6M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Citadel Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 228,542 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.46M.
- Citadel Advisors first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 28 quarters.
- Citadel Advisors's Aerie Pharmaceuticals position peaked at $85.6M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.